Clinical Trials Browser

Completed × MLN 8237 × Clear all

NCT04555837 2025-05-20

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

Phase 1/2 Completed

24 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01848067 2025-05-04

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

9 enrolled 9 charts

Prostatic Neoplasms

NCT02186509 2025-04-30

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

Phase 1 Completed

17 enrolled 11 charts

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT04479306 2024-06-04

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02293005 2022-10-04

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Phase 2 Completed

28 enrolled 11 charts

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

NCT01924260 2022-08-02

Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00853307 2022-04-08

MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Phase 2 Completed

31 enrolled 19 charts

Ovarian Neoplasms

NCT01154816 2020-05-13

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Phase 2 Completed

118 enrolled 24 charts

CNSGastrointestinalLymphoidOther hematologic neoplasmSarcoma

Neuroblastoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02560025 2020-05-05

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

Phase 2 Completed

42 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02327169 2020-02-25

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Phase 1 Completed

81 enrolled 33 charts

Advanced Nonhematologic Malignancies

NCT02259010 2019-09-20

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Phase 1 Completed

24 enrolled 26 charts

Lymphoma

NCT01601535 2019-07-31

Study of MLN8237 in Combination With Irinotecan and Temozolomide

Phase 1/2 Completed

54 enrolled 25 charts

Neuroblastoma

NCT01639911 2019-07-22

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Phase 1 Completed

BreastCNSDermatologicGastrointestinalHead & Neck

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Melanoma, Central Nervous System Neoplasms

NCT01898078 2019-06-21

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

Phase 1 Completed

26 enrolled 20 charts

Lymphoma

NCT02109328 2019-04-11

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01844583 2019-03-25

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Phase 1 Completed

55 enrolled 29 charts

Lymphoma

NCT00651664 2019-03-15

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Phase 1 Completed

59 enrolled 51 charts

Advanced Malignancies

NCT00500903 2019-03-14

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Phase 1 Completed

87 enrolled 68 charts

Advanced Malignancies

NCT00962091 2019-03-12

Study of MLN8237 in Participants With Advanced Solid Tumors

Phase 1 Completed

53 enrolled 30 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01094288 2019-02-15

A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

Phase 1 Completed

41 enrolled 31 charts

GenitourinaryOther solid neoplasm

Advanced Solid Tumors

NCT01897012 2019-01-28

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Phase 1 Completed

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01923337 2019-01-04

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01714947 2018-10-31

Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib

Phase 1 Completed

3 enrolled 32 charts

Lymphoma

NCT02319018 2018-10-09

Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors

Phase 1 Completed

Gastrointestinal

Gastrointestinal Neoplasms

NCT01540682 2018-08-29

MLN8237 in Head and Neck Cancer

Phase 1 Completed

Head and Neck Neoplasms, Laryngeal Diseases

NCT01482962 2018-07-31

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 3 Completed

271 enrolled 25 charts

Lymphoma, T-Cell, Peripheral

NCT01091428 2018-06-04

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Phase 2 Completed

191 enrolled 39 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00807495 2018-03-27

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Phase 2 Completed

48 enrolled 18 charts

Burkitt Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01397825 2018-03-27

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Phase 1/2 Completed

45 enrolled 24 charts

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01799278 2018-01-23

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Phase 2 Completed

60 enrolled 10 charts

Prostatic Neoplasms

NCT01677559 2018-01-11

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Phase 1 Completed

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT01653028 2017-11-30

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Phase 2 Completed

72 enrolled 13 charts

Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT01045421 2016-08-15

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Phase 1/2 Completed

273 enrolled 28 charts

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT01034553 2016-05-25

Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

26 enrolled 7 charts

Multiple Myeloma

NCT01466881 2016-03-10

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Phase 2 Completed

42 enrolled 10 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT02444884 2016-02-09

MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors

Phase 1 Completed

Neuroblastoma